Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687047 | 0.97 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687697 | 0.94 | CYP2D6 (0.36) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687041 | 0.87 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687516 | 0.87 | CYP2D6 (0.36) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687540 | 0.87 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687415 | 0.87 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687741 | 0.87 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687734 | 0.87 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687696 | 0.84 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL32687743 | 0.84 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, MCL1 | CYP2D6 3364/4885SMN1; SMN2 958/4885LMNA 2918/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | CYP2D6 2744/4885SMN1; SMN2 1323/4885LMNA 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.